<DOC>
	<DOC>NCT00526175</DOC>
	<brief_summary>The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease</brief_summary>
	<brief_title>LAL-BR/2001: Study Treatment to Low Risk ALL</brief_title>
	<detailed_description>REMISION INDUCTION Systemic chemotherapy: Prednisolone (PDN): - 60 mg/m2 day, i.v. or p.o., days 1 to 27 - 30 mg/m2 day, i.v. or p.o., days 28 to 35 Vincristine (VCR): 1,5 mg/m2 i.v., days 8, 15, 22 and 28. Daunorubicin (DNR): 30 mg/m2, i.v., days 8 and 15. L-asparaginase (L-ASA): 10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Cyclophosphamide (CFM): 1000 mg/m2, i.v., day 22. Intracranial chemotherapy Methotrexate (MTX), cytosine (ARA-C) and hydrocortisone, days 1 and 22 CONSOLIDATION TREATMENT (WEEKS 6 TO 14)with INTENSIFICACIÃ“N (C-1) - Mercaptopurine (MP) 50 mg/m2, p.o., days 1-7, 28-35 and 56-63 - MTX: 3g/m2, i.v., in 24 hours, days 1, 28 and 56. - VP-16: 150 mg/m2 i.v., days 14-15 and 42-43 - ARA-C: 1000 mg/m2 i.v., in 3 hours, days 14-15 and 42-43 - Intrathecal treatment, days 1, 28 and 56. REINDUCTION-CONSOLIDATION TREATMENT (R-C) (WEEKS 15 TO 23) Dexamethasone (DXM): - 6 mg/m2 day, p.o., days 1-21 - 3 mg/m2 day, p.o. or i.v., days 22-28 VCR: 1,5 mg/m2, i.v., days 1, 8 and 15 DNR: 30 mg/m2, i.v., days 1 and 8 L-ASA: 10.000 UI/m2 i.m. or i.v., days 8 and 9, 15 and 16, 22 and 23. CFM 1000 mg/m2 day, i.v., day 22 Mercaptopurine (MP) 50 mg/m2, p.o., days 35-42 MTX: 3g/m2, i.v., in 24 hours, day 35. VP-16: 150 mg/m2 i.v., days 49-50 ARA-C: 1.000 mg/m2 i.v., in 3 hours, days 49-50 Intrathecal treatment days 1 and 35. MAINTENANCE TREATMENT (M-1) Continuous treatment - MP 50 mg/m2/day, p.o. - MTX 20 mg/m2/week, i.m. Reinductions - VCR: 1,5 mg/m2 i.v., day 1. - PDN: 30 mg/m2/day, i.v. or p.o., days 1 to 7 - L-ASA: 20.000 UI/m2, i.m. or i.v., day 1. - Intrathecal treatment day 1 Five cycles, weeks 24, 30, 36, 42 and 48. During the week of administration cycle, continuous chemotherapy should be suspended. Intrathecal treatment: At the start of any reinduction cycle MAINTENANCE TREATMENT (M-2) (WEEKS 55-108) - MP 50 mg/m2/day, p.o. - MTX 20 mg/m2/week, i.m. - Intrathecal treatment, weeks 54 and 108 At the end of treatment should be done the study of MRD (flux cytometry)</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnoses of low risk acute lymphoblastic leukemia in children no treated previously Mature BALL (FABL3) or with cytogenetic ALL "Burkittlike" alterations (t[8;14], t[2;8], t[8;22]) Mixed forms of ALL Acute Leukemia no differentiate Patients with coronary disorders, valvular or hypertensive cardiopathy Patients with chronic liver disorders Chronic pulmonary disorders Renal insufficiency Neurologic disfunctions ECOG 3 and 4 No signed consent form</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Minimal Residual Disease</keyword>
</DOC>